|
1
|
Jemal A, Bray F, Centerm M, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan C, Qian X, Guan Z, Yang B, Ge Y, Wang
F and Cai J: Potential biomarkers for esophageal cancer.
Springerplus. 5:4672016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohashi S, Miyamoto S, Kikuchi O, Goto T,
Amanuma Y and Muto M: Recent advances from basic and clinical
studies of esophageal squamous cell carcinoma. Gastroenterology.
149:1700–1715. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kang X, Chen K, Li Y, Li J, D'Amico TA and
Chen X: Personalized targeted therapy for esophageal squamous cell
carcinoma. World J Gastroenterol. 21:7648–7658. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan X, Xu H and Yan Z: Functional
perspective and implications of gene expression by noncoding RNAs.
Cancer Transl Med. 1:137–152. 2015. View Article : Google Scholar
|
|
7
|
Svoronos AA, Engelman DM and Slack FJ:
OncomiR or tumor suppressor? The duplicity of microRNAs in cancer.
Cancer Res. 76:3666–3670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Otero-Albiol D and Felipe-Abrio B:
MicroRNA regulating metabolic reprogramming in tumor cells: New
tumor markers. Cancer Transl Med. 2:175–181. 2016. View Article : Google Scholar
|
|
9
|
Rupaimoole R, Calin GA, Lopez-Berestein G
and Sood AK: miRNA deregulation in cancer cells and the tumor
microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang XJ, Si RH, Liang YH, Ma BQ, Jiang ZB,
Wang B and Gao P: Mir-30d increases intracellular survival of
Helicobacter pylori through inhibition of autophagy pathway. World
J Gastroenterol. 22:3978–3991. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esposito F, Tornincasa M, Pallante P,
Federico A, Borbone E, Pierantoni GM and Fusco A: Down-regulation
of the miR-25 and miR-30d contributes to the development of
anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J
Clin Endocrinol Metab. 97:E710–E718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao J, Liang L, Huang S, Ding J, Tan N,
Zhao Y, Yan M, Ge C, Zhang Z, Chen T, et al: MicroRNA-30d promotes
tumor invasion and metastasis by targeting Galphai2 in
hepatocellular carcinoma. Hepatology. 51:846–856. 2010.PubMed/NCBI
|
|
13
|
Kobayashi N, Uemura H, Nagahama K, Okudela
K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, et al:
Identification of miR-30d as a novel prognostic marker of prostate
cancer. Oncotarget. 3:1455–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yu H, Lin X, Wang F, Zhang B, Wang W, Shi
H, Zou B and Zhao J: Proliferation inhibition and the underlying
molecular mechanisms of microRNA-30d in renal carcinoma cells.
Oncol Lett. 7:799–804. 2014.PubMed/NCBI
|
|
15
|
Chou CH, Chang NW, Shrestha S, Hsu SD, Lin
YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, et al: miRTarBase
2016: Updates to the experimentally validated miRNA-target
interactions database. Nucleic Acids Res. 44:D239–D247. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
He LR, Liu MZ, Li BK, Jia WH, Zhang Y,
Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, et al: High
expression of EZH2 is associated with tumor aggressiveness and poor
prognosis in patients with esophageal squamous cell carcinoma
treated with definitive chemoradiotherapy. Int J Cancer.
127:138–147. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ha SY and Kim SH: Co-expression of Bmi1
and EZH2 as an independent poor prognostic factor in esophageal
squamous cell carcinoma. Pathol Res Pract. 208:462–469. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang SD, Yuan Y, Zhuang CW, Li BL, Gong
DJ, Wang SG, Zeng ZY and Cheng HZ: MicroRNA-98 and microRNA-214
post-transcriptionally regulate enhancer of zeste homolog 2 and
inhibit migration and invasion in human esophageal squamous cell
carcinoma. Mol Cancer. 11:512012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sakai NS, Samia-Aly E, Barbera M and
Fitzgerald RC: A review of the current understanding and clinical
utility of miRNAs in esophageal cancer. Semin Cancer Biol.
23:512–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mayne GC, Hussey DJ and Watson DI:
MicroRNAs and esophageal cancer - implications for pathogenesis and
therapy. Curr Pharm Des. 19:1211–1226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Trošelj K Gall, Novak Kujundzic R and
Ugarkovic D: Polycomb repressive complex's evolutionary conserved
function: The role of EZH2 status and cellular background. Clin
Epigenetics. 8:552016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Italiano A: Role of the EZH2 histone
methyltransferase as a therapeutic target in cancer. Pharmacol
Ther. 165:26–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herviou L, Cavalli G, Cartron G, Klein B
and Moreaux J: EZH2 in normal hematopoiesis and hematological
malignancies. Oncotarget. 7:2284–2296. 2016.PubMed/NCBI
|
|
24
|
Kim KH and Roberts CW: Targeting EZH2 in
cancer. Nat Med. 22:128–134. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martínez-Fernández M, Rubio C, Segovia C,
López-Calderón FF, Dueñas M and Paramio JM: EZH2 in bladder cancer,
a promising therapeutic target. Int J Mol Sci. 16:27107–27132.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yin Y, Qiu S and Peng Y: Functional roles
of enhancer of zeste homolog 2 in gliomas. Gene. 576:189–194. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu B, Konze KD, Jin J and Wang GG:
Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp
Hematol. 43:698–712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han Li C and Chen Y: Targeting EZH2 for
cancer therapy: Progress and perspective. Curr Protein Pept Sci.
16:559–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
